Joerg Kreuzer

Medicine · Health Sciences

12h-index936citations25works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Atrial Fibrillation Management and Outcomes(10), Venous Thromboembolism Diagnosis and Management(8), Lipid metabolism and disorders(3), Diabetes, Cardiovascular Risks, and Lipoproteins(2), Lipoproteins and Cardiovascular Health(2)

Publications25 total

Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial
American Heart Journal·2019· 14 cited
Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER<sup>®</sup>, RE-COVER™ II, and RE-MEDY™
Vascular Medicine·2016· 89 cited
CLINICAL OUTCOMES OF ATRIAL FIBRILLATION PATIENTS RECEIVING DIGOXIN IN THE RE-LY ® TRIAL
Journal of the American College of Cardiology·2016· 2 cited
Treatment of acute pulmonary embolism with dabigatran versus warfarin
Thrombosis and Haemostasis·2016· 27 cited
Abstract 11473: Dabigatran Treatment Simulation in Patients Undergoing Maintenance Hemodialysis
Circulation·2015
Abstract 12422: Influence of Polypharmacy on the Efficacy And Safety Of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER <sup>®</sup> and RE-COVER II <sup>™</sup>
Circulation·2015· 1 cited
Abstract 12422: Influence of Polypharmacy on the Efficacy And Safety Of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER® and RE-COVER II™
Circulation·2015· 2 cited
Dabigatran treatment simulation in patients undergoing maintenance haemodialysis
Thrombosis and Haemostasis·2015· 12 cited
Post-Hoc Analysis of RE-MEDY™ Demonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism
Blood·2014· 2 cited
Influence of Thrombophilia on the Efficacy of Dabigatran Versus Warfarin for the Extended Treatment of Acute Venous Thromboembolism in RE-MEDY™
Blood·2014· 10 cited
Influence of Age and Renal Function on Efficacy and Safety of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER™ and RE-COVER™ II
Blood·2014· 7 cited
Abstract 18594: Efficacy of Dabigatran versus Warfarin in Patients With Acute Venous Thromboembolism and Thrombophilia: A Pooled Analysis of RE-COVER™ and RE-COVER™ II
Circulation·2014· 4 cited
Influence Of Age On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis Of RE-Cover and RE-Cover II
Blood·2013· 13 cited
Percutaneous Aortic “Valve in Valve” Implantation for Severe Aortic Regurgitation in a Degenerated Bioprosthesis
Circulation Cardiovascular Interventions·2010· 11 cited
Long-term Administration of 3-deazaadenosine Does Not Alter Progression of Advanced Atherosclerotic Lesions in Apolipoprotein E-deficient Mice
Journal of Cardiovascular Pharmacology·2007· 3 cited
Melagatran Reduces Advanced Atherosclerotic Lesion Size and May Promote Plaque Stability in Apolipoprotein E– Deficient Mice
Arteriosclerosis Thrombosis and Vascular Biology·2006· 97 cited
Serum Adiponectin Levels Are an Independent Predictor of the Extent of Coronary Artery Disease in Men
Journal of the American College of Cardiology·2006· 62 cited
Decreased Plasma Lipoprotein Lipase in Hypoadiponectinemia
Diabetes Care·2004· 138 citedOpen Access
1082-181 Production of reactive oxygen species by mononuclear cells correlates with the severity of coronary heart disease and NADPH oxidase expression
Journal of the American College of Cardiology·2004
Transfection with DNA of soluble VCAM-1 causes monocyte chemotaxis and increased endothelial cell staining: A new gene-therapeutic approach for angiogenesis?
Journal of the American College of Cardiology·2003
page 1 of 2Next →

Frequent Co-authors

Samuel Z. Goldhaber(9), Sebastian Schellong(9), Sam Schulman(9), Ajay K. Kakkar(8), Martin Feuring(8), Klaus A. Dugi(6), Henry Eriksson(6), Mandy Fraessdorf(5), Clive Kearon(5), Jochen G. Schneider(4), Hugo A. Katus(4), Nikolaus Schmidt(3), Peter P. Nawroth(3), Henry Eriksson(3), Martina Brueckmann(3), Patrick Mismetti(3), Stefan Hantel(3), Christiane Viedt(2), Maximilian von Eynatten(2), Per M. Humpert(2)